Utilization of tissue-free minimal residual disease testing in colorectal cancer patients from Asia and Middle East

IntroductionThe presence of minimal residual disease (MRD) after curative-intent surgery for early-stage cancers is associated with disease recurrence. Circulating tumour deoxyribonucleic acid (ctDNA) has emerged as a promising biomarker for MRD assessment in patients with colorectal cancer (CRC) wh...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Suyog Jain, Shaheenah Dawood, Viraj Lavingia, Dan Aderka, Esther Tahover, Yao-Yu Hsieh, Mark Temper, Alesya Goldman, Marwan AI. Akasheh, Steve Olsen, Sandra San Hsing, Nisarg Joshi, Hsiao-Yu Jen
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2024-09-01
coleção:	Frontiers in Oncology
Assuntos:	MRD - molecular residual disease CRC - colorectal cancer ctDNA - circulating tumour DNA liquid biopsy Reveal epigenomics
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1426941/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!